Canada markets close in 2 minutes
  • S&P/TSX

    20,228.13
    +70.48 (+0.35%)
     
  • S&P 500

    4,245.09
    -10.06 (-0.24%)
     
  • DOW

    34,290.08
    -103.67 (-0.30%)
     
  • CAD/USD

    0.8205
    -0.0029 (-0.35%)
     
  • CRUDE OIL

    72.23
    +1.35 (+1.90%)
     
  • BTC-CAD

    48,684.21
    +90.75 (+0.19%)
     
  • CMC Crypto 200

    994.72
    -15.89 (-1.57%)
     
  • GOLD FUTURES

    1,860.20
    -5.70 (-0.31%)
     
  • RUSSELL 2000

    2,315.69
    -10.46 (-0.45%)
     
  • 10-Yr Bond

    1.4990
    -0.0020 (-0.13%)
     
  • NASDAQ

    14,067.14
    -107.00 (-0.75%)
     
  • VOLATILITY

    16.95
    +0.56 (+3.42%)
     
  • FTSE

    7,172.48
    +25.80 (+0.36%)
     
  • NIKKEI 225

    29,441.30
    +279.50 (+0.96%)
     
  • CAD/EUR

    0.6763
    -0.0030 (-0.44%)
     

Bausch Health exploring potential sale of eye-care business - Bloomberg News

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

(Reuters) - Canadian drugmaker Bausch Health Companies Inc is exploring a potential sale of its eye-care business, Bloomberg News reported on Wednesday, citing people with knowledge of the matter.

Bausch had last year said it was spinning off its eye-care unit, Bausch + Lomb, into a separate publicly listed company, seven years after acquiring it for nearly $9 billion.

The unit includes eye-health products like contact lenses and surgical devices. Its Bausch + Lomb segment raked in $1.24 billion in the fourth quarter.

The drugmaker has not made a final decision yet and could still opt to spin off or keep the business, the Bloomberg report said.

The company did not immediately respond to Reuters request for comment.

It has had calls from activist investor Glenview Capital Management for Bausch to spin-off Bausch + Lomb by year-end.

(Reporting by Trisha Roy in Bengaluru; Editing by Arun Koyyur)